A California jury has directed Johnson & Johnson to pay $40 million to two women who allege that years of using the company’s talc-based baby powder contributed to their ovarian cancer diagnoses. The women testified about their extensive medical treatments and argued that the company was aware of the potential risks associated with its product. Johnson & Johnson intends to appeal the verdict, asserting that the evidence does not justify the jury’s decision.
Details of the Case
The lawsuit involved two California residents, diagnosed with ovarian cancer in 2014 and 2018, respectively. Both women reported using Johnson & Johnson’s baby powder after bathing for around 40 years. Their testimonies detailed their severe medical conditions, which required major surgeries and multiple rounds of chemotherapy. Andy Birchfield, their attorney, emphasized during the trial that the company had prior knowledge of the associated risks but chose to conceal this from consumers, highlighting alleged negligence in protecting its customers.
Johnson & Johnson’s Defense
In defense of the claims, Johnson & Johnson’s attorney, Allison Brown, argued that the evidence presented was insufficient. She pointed out that no major U.S. health authority supports a link between talc and ovarian cancer, nor is there any scientific study proving that talc can migrate from the skin to reproductive organs. The company maintains that its products are safe, asbestos-free, and do not cause cancer. Erik Haas, the company’s vice president of litigation, announced plans to appeal the verdict, calling it an “aberrant” decision that the company aims to overturn.
Ongoing Legal Challenges
Johnson & Johnson is currently facing a significant number of lawsuits, with over 67,000 plaintiffs claiming their use of talc products led to cancer diagnoses. The company ceased the sale of talc-based baby powder in the U.S. in 2020, transitioning to a cornstarch alternative. Federal courts have rejected previous attempts by Johnson & Johnson to resolve these lawsuits through bankruptcy, with the most recent dismissal occurring in April. The cases involving the two women are the first to proceed to trial following these bankruptcy attempts.
Historical Context and Future Implications
Prior to the bankruptcy proceedings, Johnson & Johnson had a mixed record in talc-related trials, with some verdicts reaching as high as $4.69 billion awarded to women claiming their ovarian cancer resulted from the baby powder. While the company has won some trials, others have led to significant judgments against it. The majority of the lawsuits focus on ovarian cancer, although a smaller number involve claims related to mesothelioma, a rare and deadly cancer. Johnson & Johnson has settled some mesothelioma claims but has not established a nationwide settlement, resulting in ongoing trials in state courts. Recently, the company has faced considerable verdicts in mesothelioma cases, including a notable judgment exceeding $900 million in Los Angeles last October.
Digihunt is not a financial advisor and this is not investment advice.









